Control experiments showed that TBAI played the key role in
the reaction (Table 1, entry 3). It is noteworthy that while
using a catalytic amount of TBAI ensures a good result,
too much TBAI has negative effect on the reaction (Table 1,
entry 10). The reaction also took place in the absence of
BF3ꢀEt2O, but the yield of 3a was lower (Table 1, entry 8).
On the other hand, using 1.0 equiv. of BF3ꢀEt2O was less
favorable for the reaction, consistent with our previous
findings (Table 1, entry 9).4 Besides TBAI, NaI and KI were
also capable of catalyzing the reaction, indicating that an
ammonium counterion was not necessary during the reaction.10
To examine the scope of this protocol, the optimized condi-
tions (Table 1, entry 6) were then applied to the synthesis of a
variety of substituted imidazo[1,2-a]pyridines 3 from 2-amino-
pyridines 1 and 1,3-dicarbonyl compounds 2.z The results are
listed in Table 2. 2-Phenyl-imidazo[1,2-a]pyridine-3-carboxy-
lates were prepared in good yields except for the chloro-
substituted 3e and 3f, in which cases the reaction was not
complete even after prolonged reaction time (Table 2, entries 5–6).
The structure of 3d was confirmed by X-ray crystallographic
analysis.11 The reaction can also be used to prepare 2-alkyl
substituted imidazo[1,2-a]pyridine-3-carboxylates (3m–3v),
and 2-alkyl-3-acyl imidazo[1,2-a]pyridines (3w–3z). Compounds
3 are useful intermediates for the synthesis of pharmaceutically
important compounds.12
likely the working mechanism. Another alternative mecha-
nism, which involves firstly the condensation between 1 and 2,
and then the oxidation of thus formed enamine ester, is not
possible as the condensation of 1a and 2a cannot take place in
refluxing acetonitrile.10
In summary, this work demonstrates that the direct oxida-
tive C–N coupling between 2-aminopyridines and b-keto esters
or 1,3-diones can be effected by using TBAI as the catalyst and
TBHP as the terminal oxidant. The reaction constitutes a
simple and economical protocol for the synthesis of
imidazo[1,2-a]pyridines.
The authors thank the National Natural Science Foundation
of China (No. 20772053) for financial support.
Notes and references
z General procedure for the synthesis of substituted imidazo-
[1,2-a]pyridines (3) from 2-aminopyridines (1) and b-keto esters and
acetylacetone (2): a mixture of 1.0 mmol of 2, 1.5 mmol of 1, 0.1 mmol
of TBAI, 2.0 mmol of TBHP (70% in water) and 26 mL of BF3ꢀEt2O
(0.2 mmol) in 5 mL of CH3CN was stirred in a 15 mL Pyrex screw-cap
pressure tube at 80 1C for the indicated period of time shown in
Table 2. After the reaction finished as indicated by TLC, the reaction
mixture was cooled to room temperature, and then poured into 15 mL
saturated Na2SO3 solution. The product was extracted with EtOAc
(20 mL ꢂ 3). The combined organic layer was washed with brine and
dried with anhydrous Na2SO4. After filtration, the solvent was
removed under reduced pressure, and the residue was treated with
silica gel chromatography to give product 3.
To account for the reaction process described above, a
mechanism (Scheme 1, path a) was proposed based on
Ishihara’s study6 and our experiments. In this mechanism,
MI is firstly oxidized by TBHP to M+[IO2]ꢁ (A), and the latter
reacts with 2 to give intermediate C. Nucleophilic attack of C
by 1 affords E, from which product 3 is generated. The
released M+[IO]ꢁ (B) is reoxidized to A by TBHP. Catalytic
amount of BF3ꢀEt2O has beneficial effect on the reaction,
probably because it can enhance the electrophilicity of A as
well as facilitate the removal of B from C. On the other hand,
using 1 equiv. BF3ꢀEt2O hampers the function of 1 as the
nucleophile, thus resulting in lowering of the yield.4 It is also
possible that the active oxidant was B, which reacted with 2 to
generate D (Scheme 1, path b). However, control experiments
showed that the reaction of 1a with ethyl 2-iodo-3-oxo-3-
phenylpropanoate only affords 3a in low yield. Besides, we
failed to obtain D when 2a was treated with TBAI and TBHP
in the presence of BF3ꢀEt2O. Therefore, path b seems less
1 A. R. Katritzky, Y.-J. Xu and H. Tu, J. Org. Chem., 2003,
68, 4935, and cited references therein.
2 N. Chernyak and V. Gevorgyan, Angew. Chem., Int. Ed., 2010,
49, 2743, and cited references therein.
3 For recent examples, see: (a) G. Trapani, V. Laquintana,
N. Denora, A. Trapani, A. Lopedota, A. Latrofa, M. Franco,
M. Serra, M. G. Pisu, I. Floris, E. Sanna, G. Biggio and G. Liso,
J. Med. Chem., 2005, 48, 292; (b) V. Laquintana, N. Denora,
A. Lopedota, H. Suzuki, M. Sawada, M. Serra, G. Biggio,
A. Latrofa, G. Trapani and G. Liso, Bioconjugate Chem., 2007,
18, 1397; (c) N. Denora, V. Laquintana, M. G. Pisu, R. Dore,
L. Murru, A. Latrofa, G. Trapani and E. Sanna, J. Med. Chem.,
2008, 51, 6876; (d) H. Kishino, M. Moriya, S. Sakuraba,
T. Sakamoto, H. Takahashi, T. Suzuki, R. Moriya, M. Ito,
H. Iwaasa, N. Takenaga, A. Ishihara, A. Kanatani, N. Sato and
T. Fukami, Bioorg. Med. Chem. Lett., 2009, 19, 4589.
4 X. Wang, L. Ma and W. Yu, Synthesis, 2011, 2445.
5 (a) R. D. Richardson and T. Wirth, Angew. Chem., Int. Ed., 2006,
45, 4402; (b) M. Ochiai and K. Miyamoto, Eur. J. Org. Chem.,
2008, 4229; (c) T. Dohi and Y. Kita, Chem. Commun., 2009, 2073;
(d) T. Dohi, Chem. Pharm. Bull., 2010, 58, 135.
6 (a) M. Uyanik, H. Okamoto, T. Yasui and K. Ishihara, Science,
2010, 328, 1376; (b) M. Uyanik and K. Ishihara, Chim. Oggi., 2011,
29, 18; (c) M. Uyanik, D. Suzuki, T. Yasui and K. Ishihara, Angew.
Chem., Int. Ed., 2011, 50, 5331.
7 M. Kirihara, Y. Asai, S. Ogawa, T. Noguchi, A. Hatano and
Y. Hirai, Synthesis, 2007, 3286.
8 L. Chen, E. Shi, Z. Liu, S. Chen, W. Wei, H. Li, K. Xu and
X. Wan, Chem.–Eur. J., 2011, 17, 4085. However, in this work, a
free radical mechanism was proposed by the authors to rationalize
the observations.
9 After submission of this paper, a work dealing with TBAI-
catalyzed C–N oxidative coupling with TBHP as the oxidant was
published. See: T. Froehr, C. P. Sindlinger, U. Kloeckner,
P. Finkbeiner and B. J. Nachtsheim, Org. Lett., 2011, 13, 3754.
10 Please see ESIw for more details.
11 CCDC 824738.
12 (a) P. George and C. Giron, Patent Application US 4,650,796,
1987; (b) G. Trapani, M. Franco, L. Ricciardi, A. Latrofa,
G. Genchi, E. Sanna, F. Tuveri, E. Cagetti, G. Biggio and
G. Liso, J. Med. Chem., 1997, 40, 3109.
Scheme 1
c
This journal is The Royal Society of Chemistry 2011
Chem. Commun., 2011, 47, 11333–11335 11335